These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
479 related articles for article (PubMed ID: 28072762)
1. Giving AXL the axe: targeting AXL in human malignancy. Gay CM; Balaji K; Byers LA Br J Cancer; 2017 Feb; 116(4):415-423. PubMed ID: 28072762 [TBL] [Abstract][Full Text] [Related]
2. AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations. Falcone I; Conciatori F; Bazzichetto C; Bria E; Carbognin L; Malaguti P; Ferretti G; Cognetti F; Milella M; Ciuffreda L Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33182542 [TBL] [Abstract][Full Text] [Related]
3. The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications. Paccez JD; Vogelsang M; Parker MI; Zerbini LF Int J Cancer; 2014 Mar; 134(5):1024-33. PubMed ID: 23649974 [TBL] [Abstract][Full Text] [Related]
4. Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer. Lin JZ; Wang ZJ; De W; Zheng M; Xu WZ; Wu HF; Armstrong A; Zhu JG Oncotarget; 2017 Jun; 8(25):41064-41077. PubMed ID: 28455956 [TBL] [Abstract][Full Text] [Related]
5. Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies. Schoumacher M; Burbridge M Curr Oncol Rep; 2017 Mar; 19(3):19. PubMed ID: 28251492 [TBL] [Abstract][Full Text] [Related]
6. MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents. McDaniel NK; Cummings CT; Iida M; Hülse J; Pearson HE; Vasileiadi E; Parker RE; Orbuch RA; Ondracek OJ; Welke NB; Kang GH; Davies KD; Wang X; Frye SV; Earp HS; Harari PM; Kimple RJ; DeRyckere D; Graham DK; Wheeler DL Mol Cancer Ther; 2018 Nov; 17(11):2297-2308. PubMed ID: 30093568 [TBL] [Abstract][Full Text] [Related]
7. Accelerating AXL targeting for TNBC therapy. Khera L; Lev S Int J Biochem Cell Biol; 2021 Oct; 139():106057. PubMed ID: 34403827 [TBL] [Abstract][Full Text] [Related]
9. AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells. Asiedu MK; Beauchamp-Perez FD; Ingle JN; Behrens MD; Radisky DC; Knutson KL Oncogene; 2014 Mar; 33(10):1316-24. PubMed ID: 23474758 [TBL] [Abstract][Full Text] [Related]
10. Apoptotic Bodies Elicit Gas6-Mediated Migration of AXL-Expressing Tumor Cells. Zweemer AJM; French CB; Mesfin J; Gordonov S; Meyer AS; Lauffenburger DA Mol Cancer Res; 2017 Dec; 15(12):1656-1666. PubMed ID: 28923840 [TBL] [Abstract][Full Text] [Related]
11. Role of the receptor tyrosine kinase Axl in hepatocellular carcinoma and its clinical relevance. Niu ZS; Niu XJ; Wang WH Future Oncol; 2019 Feb; 15(6):653-662. PubMed ID: 30648886 [TBL] [Abstract][Full Text] [Related]
12. AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity. Terry S; Abdou A; Engelsen AST; Buart S; Dessen P; Corgnac S; Collares D; Meurice G; Gausdal G; Baud V; Saintigny P; Lorens JB; Thiery JP; Mami-Chouaib F; Chouaib S Cancer Immunol Res; 2019 Nov; 7(11):1789-1802. PubMed ID: 31488404 [TBL] [Abstract][Full Text] [Related]
13. Gene of the month: Axl. Brown M; Black JR; Sharma R; Stebbing J; Pinato DJ J Clin Pathol; 2016 May; 69(5):391-7. PubMed ID: 26951083 [TBL] [Abstract][Full Text] [Related]
14. The Role of the Receptor Tyrosine Kinase Axl in Carcinogenesis and Development of Therapeutic Resistance: An Overview of Molecular Mechanisms and Future Applications. Wium M; Ajayi-Smith AF; Paccez JD; Zerbini LF Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33806258 [TBL] [Abstract][Full Text] [Related]
15. Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells. Bansal N; Mishra PJ; Stein M; DiPaola RS; Bertino JR Oncotarget; 2015 Jun; 6(17):15321-31. PubMed ID: 26036314 [TBL] [Abstract][Full Text] [Related]
17. The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Graham DK; DeRyckere D; Davies KD; Earp HS Nat Rev Cancer; 2014 Dec; 14(12):769-85. PubMed ID: 25568918 [TBL] [Abstract][Full Text] [Related]
18. Targeting Axl favors an antitumorigenic microenvironment that enhances immunotherapy responses by decreasing Hif-1α levels. Goyette MA; Elkholi IE; Apcher C; Kuasne H; Rothlin CV; Muller WJ; Richard DE; Park M; Gratton JP; Côté JF Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34266948 [TBL] [Abstract][Full Text] [Related]
19. Overexpression of MERTK receptor tyrosine kinase in epithelial cancer cells drives efferocytosis in a gain-of-function capacity. Nguyen KQ; Tsou WI; Calarese DA; Kimani SG; Singh S; Hsieh S; Liu Y; Lu B; Wu Y; Garforth SJ; Almo SC; Kotenko SV; Birge RB J Biol Chem; 2014 Sep; 289(37):25737-49. PubMed ID: 25074939 [TBL] [Abstract][Full Text] [Related]
20. Axl and Mer Receptor Tyrosine Kinases: Distinct and Nonoverlapping Roles in Inflammation and Cancer? Dransfield I; Farnworth S Adv Exp Med Biol; 2016; 930():113-32. PubMed ID: 27558819 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]